Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Philip A. Sharp sold 15,000 shares of the stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $129.00, for a total value of $1,935,000.00. Following the transaction, the director now directly owns 155,795 shares of the company’s stock, valued at approximately $20,097,555. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded up $2.12 during trading on Tuesday, reaching $144.16. The company had a trading volume of 1,920,000 shares, compared to its average volume of 717,579. The stock has a market capitalization of $14,180.00, a price-to-earnings ratio of -26.65 and a beta of 2.67. Alnylam Pharmaceuticals, Inc. has a 52 week low of $46.90 and a 52 week high of $152.75. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing the consensus estimate of ($1.38) by ($0.10). The business had revenue of $37.90 million during the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The company’s revenue was up 116.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.32) earnings per share. equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -6.88 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of ALNY. Strs Ohio purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $141,000. CENTRAL TRUST Co grew its position in Alnylam Pharmaceuticals by 746.3% in the fourth quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,000 shares during the period. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $165,000. The Manufacturers Life Insurance Company grew its position in Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 167 shares during the period. Finally, Segall Bryant & Hamill LLC purchased a new position in Alnylam Pharmaceuticals in the third quarter worth approximately $235,000. Institutional investors own 92.44% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.